S C Deresinski

Summary

Country: USA

Publications

  1. ncbi The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials
    Stanley C Deresinski
    Stanford University Medical Center, San Jose, CA 94305, USA
    Diagn Microbiol Infect Dis 61:103-9. 2008
  2. ncbi Coccidioidomycosis: efficacy of new agents and future prospects
    S C Deresinski
    Department of Medicine, Stanford University, Stanford, California, USA
    Curr Opin Infect Dis 14:693-6. 2001
  3. ncbi Coccidioides immitis as a potential bioweapon
    Stan Deresinski
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Semin Respir Infect 18:216-9. 2003
  4. ncbi Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 45:S177-83. 2007
  5. ncbi Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class
    Stanley C Deresinski
    Stanford University Medical Center, San Jose, CA 94062, USA
    Diagn Microbiol Infect Dis 61:82-5. 2008
  6. ncbi Bacteriophage therapy: exploiting smaller fleas
    Stan Deresinski
    Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Infect Dis 48:1096-101. 2009
  7. ncbi Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial
    Carol A Kemper
    Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA
    J Infect Dis 187:1327-31. 2003
  8. ncbi Caspofungin
    Stanley C Deresinski
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, 95128, USA
    Clin Infect Dis 36:1445-57. 2003

Detail Information

Publications8

  1. ncbi The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials
    Stanley C Deresinski
    Stanford University Medical Center, San Jose, CA 94305, USA
    Diagn Microbiol Infect Dis 61:103-9. 2008
    ..This article also addresses the results of these trials in the context of the current medical need for safe broad-spectrum antimicrobial agents with MRSA coverage...
  2. ncbi Coccidioidomycosis: efficacy of new agents and future prospects
    S C Deresinski
    Department of Medicine, Stanford University, Stanford, California, USA
    Curr Opin Infect Dis 14:693-6. 2001
    ..Investigational agents that have activity against C. immitis include posaconazole, voriconazole, caspofungin, and sordarin derivatives...
  3. ncbi Coccidioides immitis as a potential bioweapon
    Stan Deresinski
    Santa Clara Valley Medical Center, San Jose, CA 95128, USA
    Semin Respir Infect 18:216-9. 2003
    ..C. immitis could be used as a weapon of bioterror or biowarfare with aerosol delivery. Its use for this purpose would, however, present a number of obstacles and its effect would be uncertain and most probably limited...
  4. ncbi Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 45:S177-83. 2007
    ..An appropriate response to this information often involves de-escalation of therapy or even its discontinuation...
  5. ncbi Ceftobiprole: breaking therapeutic dogmas of the beta-lactam class
    Stanley C Deresinski
    Stanford University Medical Center, San Jose, CA 94062, USA
    Diagn Microbiol Infect Dis 61:82-5. 2008
  6. ncbi Bacteriophage therapy: exploiting smaller fleas
    Stan Deresinski
    Department of Medicine, Division of Infectious Disease and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA
    Clin Infect Dis 48:1096-101. 2009
    ..This brief overview of the history and status of phage therapy, along with speculation about its future, provides a background for understanding of this imminent therapeutic modality...
  7. ncbi Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial
    Carol A Kemper
    Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, San Jose, California, USA
    J Infect Dis 187:1327-31. 2003
    ..004). HepA vaccine was well tolerated and had no effect on the course of HIV infection or plasma HIV RNA load...
  8. ncbi Caspofungin
    Stanley C Deresinski
    Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, 95128, USA
    Clin Infect Dis 36:1445-57. 2003
    ..Caspofungin is an important addition to the antifungal pharmacopoeia...